Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/ERBIN_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/ERBIN_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/ERBIN_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/ERBIN_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/ERBIN_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/ERBIN_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/ERBIN_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/ERBIN_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/ERBIN_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/ERBIN_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00510569 | Oral cavity | EOLP | regulation of small GTPase mediated signal transduction | 51/2218 | 302/18723 | 5.67e-03 | 2.92e-02 | 51 |
GO:003052231 | Oral cavity | NEOLP | intracellular receptor signaling pathway | 61/2005 | 265/18723 | 5.22e-09 | 2.87e-07 | 61 |
GO:000716333 | Oral cavity | NEOLP | establishment or maintenance of cell polarity | 53/2005 | 218/18723 | 7.21e-09 | 3.82e-07 | 53 |
GO:000726531 | Oral cavity | NEOLP | Ras protein signal transduction | 71/2005 | 337/18723 | 1.60e-08 | 7.27e-07 | 71 |
GO:003461231 | Oral cavity | NEOLP | response to tumor necrosis factor | 55/2005 | 253/18723 | 2.23e-07 | 7.28e-06 | 55 |
GO:007135631 | Oral cavity | NEOLP | cellular response to tumor necrosis factor | 50/2005 | 229/18723 | 6.79e-07 | 1.93e-05 | 50 |
GO:000722931 | Oral cavity | NEOLP | integrin-mediated signaling pathway | 29/2005 | 107/18723 | 1.72e-06 | 4.19e-05 | 29 |
GO:003249631 | Oral cavity | NEOLP | response to lipopolysaccharide | 65/2005 | 343/18723 | 3.30e-06 | 7.40e-05 | 65 |
GO:000223731 | Oral cavity | NEOLP | response to molecule of bacterial origin | 67/2005 | 363/18723 | 5.94e-06 | 1.20e-04 | 67 |
GO:004510422 | Oral cavity | NEOLP | intermediate filament cytoskeleton organization | 17/2005 | 51/18723 | 1.25e-05 | 2.25e-04 | 17 |
GO:004510322 | Oral cavity | NEOLP | intermediate filament-based process | 17/2005 | 52/18723 | 1.67e-05 | 2.83e-04 | 17 |
GO:000222121 | Oral cavity | NEOLP | pattern recognition receptor signaling pathway | 35/2005 | 172/18723 | 1.38e-04 | 1.60e-03 | 35 |
GO:007042322 | Oral cavity | NEOLP | nucleotide-binding oligomerization domain containing signaling pathway | 10/2005 | 25/18723 | 1.39e-04 | 1.61e-03 | 10 |
GO:005109031 | Oral cavity | NEOLP | regulation of DNA-binding transcription factor activity | 72/2005 | 440/18723 | 1.66e-04 | 1.84e-03 | 72 |
GO:003587221 | Oral cavity | NEOLP | nucleotide-binding domain, leucine rich repeat containing receptor signaling pathway | 10/2005 | 26/18723 | 2.04e-04 | 2.19e-03 | 10 |
GO:000276422 | Oral cavity | NEOLP | immune response-regulating signaling pathway | 74/2005 | 468/18723 | 3.90e-04 | 3.63e-03 | 74 |
GO:000275321 | Oral cavity | NEOLP | cytoplasmic pattern recognition receptor signaling pathway | 16/2005 | 60/18723 | 4.28e-04 | 3.91e-03 | 16 |
GO:004657815 | Oral cavity | NEOLP | regulation of Ras protein signal transduction | 36/2005 | 189/18723 | 4.30e-04 | 3.92e-03 | 36 |
GO:007043112 | Oral cavity | NEOLP | nucleotide-binding oligomerization domain containing 2 signaling pathway | 7/2005 | 16/18723 | 7.62e-04 | 6.16e-03 | 7 |
GO:007042421 | Oral cavity | NEOLP | regulation of nucleotide-binding oligomerization domain containing signaling pathway | 6/2005 | 13/18723 | 1.32e-03 | 9.48e-03 | 6 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ERBIN | SNV | Missense_Mutation | novel | c.2410A>T | p.Thr804Ser | p.T804S | Q96RT1 | protein_coding | tolerated_low_confidence(0.67) | benign(0.007) | TCGA-A8-A06U-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ERBIN | SNV | Missense_Mutation | | c.1396N>A | p.Glu466Lys | p.E466K | Q96RT1 | protein_coding | deleterious(0.01) | benign(0.186) | TCGA-A8-A09G-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
ERBIN | SNV | Missense_Mutation | rs144581883 | c.3389N>A | p.Arg1130Gln | p.R1130Q | Q96RT1 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ERBIN | SNV | Missense_Mutation | | c.3872N>T | p.His1291Leu | p.H1291L | Q96RT1 | protein_coding | deleterious(0) | benign(0.331) | TCGA-AO-A0JJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophospamide | SD |
ERBIN | SNV | Missense_Mutation | novel | c.1765N>A | p.Val589Ile | p.V589I | Q96RT1 | protein_coding | tolerated(0.23) | benign(0) | TCGA-B6-A40B-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ERBIN | SNV | Missense_Mutation | | c.4072N>A | p.Asp1358Asn | p.D1358N | Q96RT1 | protein_coding | deleterious(0.02) | probably_damaging(0.917) | TCGA-BH-A0AZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | CR |
ERBIN | SNV | Missense_Mutation | | c.907N>C | p.Glu303Gln | p.E303Q | Q96RT1 | protein_coding | deleterious(0) | possibly_damaging(0.744) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD |
ERBIN | SNV | Missense_Mutation | | c.2631N>C | p.Glu877Asp | p.E877D | Q96RT1 | protein_coding | tolerated(0.94) | benign(0.022) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD |
ERBIN | SNV | Missense_Mutation | | c.3049N>A | p.Glu1017Lys | p.E1017K | Q96RT1 | protein_coding | tolerated(0.2) | benign(0.278) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD |
ERBIN | SNV | Missense_Mutation | | c.3268N>T | p.Asp1090Tyr | p.D1090Y | Q96RT1 | protein_coding | deleterious(0) | possibly_damaging(0.653) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD |